Heart failure-related cardiogenic shock (HF-CS) is now the leading etiology of cardiogenic shock (CS). Advances in temporary mechanical circulatory support (tMCS), particularly microaxial flow pumps (mAFP), alongside evolving organ procurement and heart-allocation policies, have expanded opportunities for hemodynamic stabilization, recovery, and heart replacement therapy. However, prolonged support capabilities have increased the complexity of clinical decision-making in a heterogeneous population with variable candidacy for heart replacement therapies if native heart recovery (NHR) is not achieved. Optimal use of mAFP requires integration of device-specific capabilities with patient-level hemodynamics and overall clinical context.